Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2010 Oct 2

PMID 20885926

Citations 13

Authors

Renee Vermeij

Toos Daemen

Geertruida H de Bock

Pauline de Graeff

Ninke Leffers

Annechien Lambeck

Klaske A ten Hoor

Harry Hollema

Ate G J van der Zee

Hans W Nijman

Affiliations

Soon will be listed here.

Abstract

The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a "universal" vaccine strategy. We determined the expression of tumor antigens in the context of MHC class I expression in 270 primary tumor samples using tissue microarray. Expression of tumor antigens p53, SP17, survivin, WT1, and NY-ESO-1 was observed in 120 (48.0%), 173 (68.9%), 208 (90.0%), 129 (56.3%), and 27 (11.0%) of 270 tumor specimens, respectively. In 93.2% of EOC, at least one of the investigated tumor antigens was (over)expressed. Expression of MHC class I was observed in 78.1% of EOC. In 3 out 4 primary tumors, (over)expression of a tumor antigen combined with MHC class I was observed. These results indicate that a multiepitope vaccine, comprising these antigens, could serve as a universal therapeutic vaccine for the vast majority of ovarian cancer patients.

Citing Articles

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.

Schossig P, Coskun E, Arsenic R, Horst D, Sehouli J, Bergmann E Int J Mol Sci. 2023; 24(3).

PMID: 36768616 PMC: 9916968. DOI: 10.3390/ijms24032292.

The expression of cancer-testis antigen in ovarian cancer and the development of immunotherapy.

Zhao J, Xu Z, Liu Y, Wang X, Liu X, Gao Y Am J Cancer Res. 2022; 12(2):681-694.

PMID: 35261795 PMC: 8899981.

Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade.

Zuo H, van Lierop M, Kaspers J, Bos R, Reurs A, Sarkar S Cells. 2021; 10(11).

PMID: 34831455 PMC: 8625408. DOI: 10.3390/cells10113233.

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

Fu S, Piccioni D, Liu H, Lukas R, Kesari S, Aregawi D Sci Rep. 2021; 11(1):22355.

PMID: 34785698 PMC: 8595891. DOI: 10.1038/s41598-021-01707-3.

TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice.

Tanaka Y, Wada H, Goto R, Osada T, Yamamura K, Fukaya S Sci Rep. 2020; 10(1):17284.

PMID: 33057061 PMC: 7560884. DOI: 10.1038/s41598-020-74187-6.

References

Chaise C, Buchan S, Rice J, Marquet J, Rouard H, Kuentz M . DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008; 112(7):2956-64. DOI: 10.1182/blood-2008-02-137695. View

Cannon M, Santin A, OBrien T . Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol. 2004; 16(1):87-92. DOI: 10.1097/00001703-200402000-00015. View

Chianese-Bullock K, Lewis S, Sherman N, Shannon J, Slingluff Jr C . Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine. 2009; 27(11):1764-70. PMC: 2733525. DOI: 10.1016/j.vaccine.2009.01.018. View

Hwu P, Freedman R . The immunotherapy of patients with ovarian cancer. J Immunother. 2002; 25(3):189-201. DOI: 10.1097/00002371-200205000-00001. View

Leffers N, Lambeck A, Gooden M, Hoogeboom B, Wolf R, Hamming I . Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer. 2009; 125(9):2104-13. DOI: 10.1002/ijc.24597. View

Odunsi K, Jungbluth A, Stockert E, Qian F, Gnjatic S, Tammela J . NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003; 63(18):6076-83. View

Lambeck A, Leffers N, Hoogeboom B, Sluiter W, Hamming I, Klip H . P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer. 2007; 121(3):606-14. DOI: 10.1002/ijc.22710. View

Kim C, Dessureault S, Gabrilovich D, Reintgen D, Slingluff Jr C . Immunotherapy for melanoma. Cancer Control. 2002; 9(1):22-30. DOI: 10.1177/107327480200900104. View

Kenter G, Welters M, Valentijn A, Lowik M, Berends-van der Meer D, Vloon A . Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008; 14(1):169-77. DOI: 10.1158/1078-0432.CCR-07-1881. View

10.

Barbolina M, Adley B, Shea L, Stack M . Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer. 2008; 112(7):1632-41. DOI: 10.1002/cncr.23341. View

11.

Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H . WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008; 20(2):211-20. DOI: 10.1016/j.coi.2008.04.009. View

12.

Nijman H, Lambeck A, van der Burg S, van der Zee A, Daemen T . Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med. 2005; 3:34. PMC: 1243238. DOI: 10.1186/1479-5876-3-34. View

13.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

14.

Straughn Jr J, Shaw D, Guerrero A, Bhoola S, Racelis A, Wang Z . Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer. 2004; 108(6):805-11. DOI: 10.1002/ijc.11617. View

15.

Scanlan M, Gure A, Jungbluth A, Old L, Chen Y . Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002; 188:22-32. DOI: 10.1034/j.1600-065x.2002.18803.x. View

16.

Chen Y, Hsu M, Lee P, Shin S, Mhawech-Fauceglia P, Odunsi K . Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int J Cancer. 2009; 124(12):2893-8. DOI: 10.1002/ijc.24296. View

17.

Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S . Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000; 19(2):158-63. DOI: 10.1097/00004347-200004000-00010. View

18.

Caspi R . Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008; 8(12):970-6. PMC: 2764117. DOI: 10.1038/nri2438. View

19.

Ferrandina G, Legge F, Martinelli E, Ranelletti F, Zannoni G, Lauriola L . Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 2005; 92(2):271-7. PMC: 2361852. DOI: 10.1038/sj.bjc.6602332. View

20.

Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf A . Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res. 2008; 14(11):3283-90. PMC: 2835568. DOI: 10.1158/1078-0432.CCR-07-5279. View